Apr 08, 2023
CHOSA Oncology AB has initiated the payment of final portion of the loan of 10 MSEK and interest which RhoVac AB obtained from shareholders to support the development of RV001.
CEO Peter Buhl commenting: “After several administrative steps CHOSA has initiated the pay back process to fulfill our obligations towards the loan givers. I want to thank you all for your patience and for your support in developing products for hard-to-treat cancers.”
This disclosure contains information that Chosa Oncology AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 08-04-2023 10:31 CET.